How to Buy Alkem Laboratories Ltd Shares?
You can easily buy the stocks/shares of Alkem Laboratories Ltd (ALKEM) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of Alkem Laboratories Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of ALKEM as on 15th May 2025 is ₹5125.46What is the return on Alkem Laboratories Ltd share?
The past returns of Alkem Laboratories Ltd (ALKEM) share are- Past 1 week: N/A
- Past 1 month: 14.21
- Past 3 months: 2.99
- Past 6 months: -9.77
- Past 1 year: -4.76
- Past 3 years: 56.65
- Past 5 years: 104.55
What is the Dividend yield % on Alkem Laboratories Ltd share?
The current dividend yield of Alkem Laboratories Ltd (ALKEM) is 0.93What is the Market Cap of Alkem Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alkem Laboratories Ltd (ALKEM) is ₹57882.58Cr as of 15th May 2025What is the 52 Week High and Low of Alkem Laboratories Ltd?
The 52-week high and low of Alkem Laboratories Ltd (ALKEM) is ₹6439.90 and ₹4491.65.What is the PE and PB ratio of Alkem Laboratories Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Alkem Laboratories Ltd are 26.73 and 5.40 respectively.Which sector does Alkem Laboratories Ltd belong to?
Alkem Laboratories Ltd (ALKEM) belongs to the Health Care sector & Pharmaceuticals sub-sector.What are the peers or stocks similar to Alkem Laboratories Ltd?
The peers or stocks similar to Alkem Laboratories Ltd are: and many others.Can't decide whether or not to buy Alkem Laboratories Ltd?
Worry no more! Login to Tickertape and check out Alkem Laboratories Ltd (ALKEM) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of Alkem Laboratories Ltd?
The 52-week high and low of Alkem Laboratories Ltd (ALKEM) is ₹6439.90 and ₹4491.65.1. Test Stocks FAQ for Alkem Laboratories Ltd Shares?
You can easily buy the stocks/shares of Alkem Laboratories Ltd (ALKEM) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of Alkem Laboratories Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of ALKEM as on 15th May 2025 is ₹5125.46
Alkem Laboratories Ltd
ALKEM Share Price
5,125.460.03% (-1.54)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
ALKEM Performance & Key Metrics
ALKEM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 26.73 | 5.40 | 0.93% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
ALKEM Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
ALKEM Company Profile
Alkem Laboratories Limited is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.
SUNPHARMA
PE Ratio
37.00
37.00
1Y Return
11.72%
11.72%
Buy Reco %
89.19
89.19
CIPLA
PE Ratio
23.03
23.03
1Y Return
2.55%
2.55%
Buy Reco %
71.05
71.05
DRREDDY
PE Ratio
20.02
20.02
1Y Return
11.76%
11.76%
Buy Reco %
82.05
82.05
TORNTPHARM
PE Ratio
57.53
57.53
1Y Return
13.13%
13.13%
Buy Reco %
67.74
67.74
MANKIND
PE Ratio
49.29
49.29
1Y Return
6.30%
6.30%
Buy Reco %
—
—
ALKEM Sentiment Analysis
ALKEM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ALKEM Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
ALKEM Stock Growth Drivers
ALKEM Stock Growth Drivers
0
Hmm, looks like there are nogrowth drivers
ALKEM Stock Challenges
ALKEM Stock Challenges
2Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
Loan Growth Concerns
There is uncertainty regarding the company's loan deposit ratio (LDR) and its implications for loan
ALKEM Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
ALKEM Forecasts
Price
Revenue
Earnings
ALKEM Share Price Forecast
ALKEM Share Price Forecast
2025
Current
₹4,847.50
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹4,847.50
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ALKEM Company Revenue Forecast
ALKEM Company Revenue Forecast
2025
Current
₹13.46
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹13.46
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ALKEM Stock EPS (Earnings Per Share) Forecast
ALKEM Stock EPS (Earnings Per Share) Forecast
2025
Current
₹181.11
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹181.11
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ALKEM
ALKEM
Income
Balance Sheet
Cash Flow
Annual Normal View
ALKEM Income Statement
ALKEM Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5,799.54 | 6,516.59 | 7,444.89 | 8,448.58 | 9,098.22 | 10,796.84 | 11,815.34 | 12,978.42 | 13,458.26 | 13,458.26 | ||||||||||
Raw Materials | 2,511.13 | 2,477.74 | 2,941.33 | 3,574.89 | 3,832.30 | 4,715.77 | 4,444.47 | 4,923.46 | 10,452.37 | 10,452.37 | ||||||||||
| Power & Fuel Cost | 86.34 | 112.64 | 121.48 | 130.14 | 129.95 | 162.96 | 163.94 | 162.58 | ||||||||||||
| Employee Cost | 1,003.85 | 1,191.64 | 1,362.46 | 1,505.49 | 1,621.03 | 1,962.71 | 2,131.35 | 2,201.01 | ||||||||||||
| Selling & Administrative Expenses | 1,014.86 | 1,175.61 | 1,288.44 | 1,412.40 | 1,224.58 | 1,722.20 | 2,163.71 | 2,163.46 | ||||||||||||
| Operating & Other expenses | 72.40 | 434.62 | 528.71 | 248.05 | 114.76 | 32.59 | 1,189.32 | 1,093.07 | ||||||||||||
EBITDA | 1,110.96 | 1,124.34 | 1,202.47 | 1,577.61 | 2,175.60 | 2,200.61 | 1,722.55 | 2,434.84 | 3,005.89 | 3,005.89 | ||||||||||
| Depreciation/Amortization | 101.17 | 143.03 | 193.18 | 252.76 | 274.58 | 303.96 | 310.42 | 299.30 | 357.16 | 357.16 | ||||||||||
| PBIT | 1,009.79 | 981.31 | 1,009.29 | 1,324.85 | 1,901.02 | 1,896.65 | 1,412.13 | 2,135.54 | 2,648.73 | 2,648.73 | ||||||||||
| Interest & Other Items | 45.16 | 55.33 | 54.63 | 65.06 | 58.92 | 52.37 | 107.36 | 112.41 | 121.70 | 121.70 | ||||||||||
| PBT | 964.63 | 925.98 | 954.66 | 1,259.79 | 1,842.10 | 1,844.28 | 1,304.77 | 2,023.13 | 2,527.03 | 2,527.03 | ||||||||||
| Taxes & Other Items | 72.60 | 295.04 | 194.15 | 132.72 | 257.08 | 198.66 | 320.60 | 227.36 | 361.55 | 361.55 | ||||||||||
| Net Income | 892.03 | 630.94 | 760.51 | 1,127.07 | 1,585.02 | 1,645.62 | 984.17 | 1,795.77 | 2,165.48 | 2,165.48 | ||||||||||
| EPS | 74.61 | 52.77 | 63.61 | 94.26 | 132.57 | 137.63 | 82.31 | 150.19 | 181.11 | 181.11 | ||||||||||
| DPS | 15.00 | 13.00 | 16.00 | 25.00 | 30.00 | 34.00 | 50.00 | 40.00 | 45.00 | 10.00 | ||||||||||
| Payout ratio | 0.20 | 0.25 | 0.25 | 0.27 | 0.23 | 0.25 | 0.61 | 0.27 | 0.25 | 0.06 |
ALKEM Company Updates
FY 2025FY 2025
Investor Presentation
May 29PDF
Mar 19PDF
Feb 7PDF
Nov 13PDF
FY 2023FY 2023
Investor Presentation
Aug 5PDF
ALKEM Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
ALKEM Past Performance & Peer Comparison
ALKEM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Alkem Laboratories Ltd | 26.73 | 5.40 | 0.93% |
| Sun Pharmaceutical Industries Ltd | 37.00 | 6.03 | 0.95% |
| Cipla Ltd | 23.03 | 4.53 | 1.06% |
| Dr Reddy's Laboratories Ltd | 20.02 | 4.01 | 0.59% |
ALKEM Stock Price Comparison
Compare ALKEM with any stock or ETFCompare ALKEM with any stock or ETF
ALKEM
ALKEM Holdings
ALKEM Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
ALKEM Promoter Holdings Trend
ALKEM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ALKEM Institutional Holdings Trend
ALKEM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ALKEM Shareholding Pattern
ALKEM Shareholding Pattern
ALKEM Shareholding History
ALKEM Shareholding History
Foreign Institutions
Mutual Funds Invested in ALKEM
Mutual Funds Invested in ALKEM
No mutual funds holding trends are available
Top 5 Mutual Funds holding Alkem Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3250% | Percentage of the fund’s portfolio invested in the stock 2.45% | Change in the portfolio weight of the stock over the last 3 months 2.45% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 10/81 (+23) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0363% | Percentage of the fund’s portfolio invested in the stock 2.77% | Change in the portfolio weight of the stock over the last 3 months 0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 8/107 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8838% | Percentage of the fund’s portfolio invested in the stock 1.16% | Change in the portfolio weight of the stock over the last 3 months 1.16% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 28/101 (+32) |
Compare 3-month MF holding change on Screener
smallcases containing ALKEM stock
smallcases containing ALKEM stock
Looks like this stock is not in any smallcase yet.
ALKEM Events
ALKEM Events
ALKEM Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ALKEM has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.93%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹9.30 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
ALKEM Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ALKEM has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.93%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹9.30 every year
ALKEM Upcoming Dividends
ALKEM Upcoming Dividends
No upcoming dividends are available
ALKEM Past Dividends
ALKEM Past Dividends
Cash Dividend
Ex DateEx DateAug 9, 2024
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 9, 2024
Cash Dividend
Ex DateEx DateAug 8, 2024
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 8, 2024
Cash Dividend
Ex DateEx DateFeb 15, 2024
Interim
Interim | Div/Share: ₹35.00
Dividend/Share
₹35.00
Ex DateEx Date
Feb 15, 2024
Cash Dividend
Ex DateEx DateAug 8, 2022
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Aug 8, 2022
Cash Dividend
Ex DateEx DateFeb 10, 2022
Interim
Interim | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Feb 10, 2022
ALKEM Stock News & Opinions
ALKEM Stock News & Opinions
Articles & Videos
Spotlight
Alkem Laboratories Ltd up for third straight session
Alkem Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 4975, up 2.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.12% on the day, quoting at 25133.1. The Sensex is at 82476.63, up 0.04%. Alkem Laboratories Ltd has slipped around 0.91% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has slipped around 3.86% in last one month and is currently quoting at 21826.8, up 0.42% on the day. The volume in the stock stood at 1.76 lakh shares today, compared to the daily average of 1.93 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 4995.5, up 2.03% on the day. Alkem Laboratories Ltd is down 1.81% in last one year as compared to a 8.03% jump in NIFTY and a 11.32% jump in the Nifty Pharma index.The PE of the stock is 27.89 based on TTM earnings ending March 25.Powered by Capital Market - Live
5 days agoCapital Market - Live
Spotlight
Volumes spurt at Alkem Laboratories Ltd counter
Tata Technologies Ltd, Aditya Birla Fashion & Retail Ltd, Kaynes Technology India Ltd, Sun Pharma Advanced Research Company Ltd are among the other stocks to see a surge in volumes on BSE today, 04 June 2025.Alkem Laboratories Ltd notched up volume of 18.24 lakh shares by 10:46 IST on BSE, a 446.04 fold spurt over two-week average daily volume of 4088 shares. The stock slipped 1.42% to Rs.4,922.05. Volumes stood at 8367 shares in the last session.Tata Technologies Ltd witnessed volume of 99.99 lakh shares by 10:46 IST on BSE, a 72.75 times surge over two-week average daily volume of 1.37 lakh shares. The stock dropped 1.56% to Rs.755.50. Volumes stood at 1.37 lakh shares in the last session.Aditya Birla Fashion & Retail Ltd registered volume of 397.49 lakh shares by 10:46 IST on BSE, a 47.36 fold spurt over two-week average daily volume of 8.39 lakh shares. The stock slipped 9.35% to Rs.77.94. Volumes stood at 3.75 lakh shares in the last session.Kaynes Technology India Ltd witnessed volume of 5.69 lakh shares by 10:46 IST on BSE, a 39.6 times surge over two-week average daily volume of 14375 shares. The stock dropped 0.79% to Rs.5,740.05. Volumes stood at 10611 shares in the last session.Sun Pharma Advanced Research Company Ltd registered volume of 7 lakh shares by 10:46 IST on BSE, a 4.54 fold spurt over two-week average daily volume of 1.54 lakh shares. The stock slipped 17.00% to Rs.162.35. Volumes stood at 73862 shares in the last session.Powered by Capital Market - Live
1 week agoCapital Market - Live
Earnings
Alkem Laboratories consolidated net profit rises 4.19% in the March 2025 quarter
Net profit of Alkem Laboratories rose 4.19% to Rs 305.86 crore in the quarter ended March 2025 as against Rs 293.56 crore during the previous quarter ended March 2024. Sales rose 7.08% to Rs 3143.75 crore in the quarter ended March 2025 as against Rs 2935.82 crore during the previous quarter ended March 2024. For the full year,net profit rose 20.59% to Rs 2165.48 crore in the year ended March 2025 as against Rs 1795.77 crore during the previous year ended March 2024. Sales rose 2.34% to Rs 12964.52 crore in the year ended March 2025 as against Rs 12667.58 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales3143.752935.82 7 12964.5212667.58 2 OPM %12.4513.69 -19.3817.73 - PBDT508.83463.29 10 2884.192443.92 18 PBT396.34379.86 4 2527.032144.62 18 NP305.86293.56 4 2165.481795.77 21 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Alkem Laboratories to conduct AGM
Alkem Laboratories announced that the 51th Annual General Meeting(AGM) of the company will be held on 25 August 2025.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Earnings
Alkem Laboratories standalone net profit declines 14.78% in the March 2025 quarter
Net profit of Alkem Laboratories declined 14.78% to Rs 276.94 crore in the quarter ended March 2025 as against Rs 324.97 crore during the previous quarter ended March 2024. Sales declined 13.55% to Rs 2044.94 crore in the quarter ended March 2025 as against Rs 2365.37 crore during the previous quarter ended March 2024. For the full year,net profit rose 30.55% to Rs 2280.89 crore in the year ended March 2025 as against Rs 1747.15 crore during the previous year ended March 2024. Sales rose 10.67% to Rs 8813.44 crore in the year ended March 2025 as against Rs 7963.85 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales2044.942365.37 -14 8813.447963.85 11 OPM %14.5117.23 -24.4620.98 - PBDT391.47470.63 -17 2587.151897.10 36 PBT299.83401.53 -25 2303.541657.96 39 NP276.94324.97 -15 2280.891747.15 31 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Board of Alkem Laboratories recommends final dividend
Alkem Laboratories announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 8 per equity Share (i.e. 400%) , subject to the approval of the shareholders.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Alkem Laboratories to discuss results
Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Spotlight
Alkem Labs' subsidiary concludes acquisition of 100% stake in Bombay Ortho
In February this year, Alkem Medtech had executed a binding offer outlining the terms and conditions with respect to the acquisition of 100% stake of Bombay Ortho Industries. Bombay Ortho is a manufacturer and supplier of the orthopedic implants such as hip and knee implants, which are extensively used in the orthopedic field. It had recorded turnover of Rs 5.5 crore in the year ended on 31 March 2024. The cost of this acquisition was Rs 147 crore, payable in four tranches, subject to adjustment on debt, debt like items and change in normalized working capital as on closing date. In March 2025, Alkem Medtech and Bombay Ortho had executed a share purchase and share subscription agreement in this regard. In an exchange filing made post market hours on Wednesday, Alkem Labs stated that the acquisition of 100% stake in Bombay Ortho has been completed. The proposed investment by our wholly owned subsidiary 'Alkem MedTech Private Limited' is a strategic investment which will help to gain manufacturing capabilities to participate in growing orthopedic space and leveraging Bombay Ortho's expertise within the hip and knee implants segment,' Alkem Laboratories had said in a statement. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit declined 1.8% to Rs 625.82 crore in Q3 FY25 as compared with Rs 637.37 crore in Q3 FY24. Net sales rose 1.5% YoY to Rs 3,374.28 crore in Q3 FY25. The scrip shed 0.08% to currently trade at Rs 4952.50 on the BSE. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Alkem MedTech acquires Bombay Ortho Industries
Alkem Laboratories announced that its wholly owned subsidiary, Alkem MedTech has completed the acquisition of Bombay Ortho Industries. Accordingly, Bombay Ortho Industries has become a step-down subsidiary of the company. Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Alkem Lab gains as Bioequivalence Center clears USFDA inspection without observations
The inspection, conducted from March 10 to March 13, 2025, concluded that no Form 483 had been issued. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit declined 1.8% to Rs 625.82 crore in Q3 FY25 as compared with Rs 637.37 crore in Q3 FY24. Net sales rose 1.5% YoY to Rs 3,374.28 crore in Q3 FY25.Powered by Capital Market - Live
2 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 11.76%, vs industry avg of 9.02%
Over the last 5 years, market share increased from 1.81% to 3.41%
Over the last 5 years, net income has grown at a yearly rate of 18.75%, vs industry avg of 15.29%